In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ConjuChem Biotechnologies Inc.

www.conjuchem.com

Latest From ConjuChem Biotechnologies Inc.

Soon-Shiong’s “Billion-Dollar Start-Up”: What’s He Building In There?

Patrick Soon-Shiong, MD, continues to reap financial rewards from his $2.9 billion sale of Abraxis Bioscience Inc. to Celgene Corp. in 2010. Some of the cash has gone famously to Soon-Shiong’s purchase of a slice of the Los Angeles Lakers basketball team, but much more of it has gone to his next big health care project, which he describes as his “billion-dollar start-up.”

BioPharmaceutical

Partnering and M&A round-up: 17-23 November

In a relatively quiet week for dealmaking, thanks to the Thanksgiving break in the US, Scrip's round-up highlights 15 agreements.

Metabolic Disorders Cancer

From one billionaire investor to another: NantPharm raises $125 million

Blackstone, the New York-based investment firm with $190 billion under management, has put $125 million as a minority investor into the biologics and pharmaceutical manufacturing unit of Nantworks - NantPharm - established in September 2011 by serial entrepreneur and billionaire philanthropist Patrick Soon-Shiong. The NantPharm unit is principally involved in pharmaceutical development and manufacturing.

Cancer Japan

ConjuChem files for bankruptcy

ConjuChem Biotechnologies has become the latest biotech to succumb to the pressures of the economic downturn, filing a voluntary assignment in bankruptcy under Canada's Bankruptcy and Insolvency Act.

Metabolic Disorders Canada
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cardiovascular
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • RedCell Inc.
  • ConjuChem Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • ConjuChem Biotechnologies Inc.
  • Senior Management
  • Mark D Perrin, Pres. & CEO
    Thomas R Ulich, MD, EVP, R&D
    Chantal Lapointe, VP, Fin.
  • Contact Info
  • ConjuChem Biotechnologies Inc.
    Phone: (514) 844-5558
    225 President-Kennedy Ave., 3rd Fl.
    Ste. 3950
    Montreal, H2X 3Y8
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register